PMID- 26698263
OWN - NLM
STAT- MEDLINE
DCOM- 20160808
LR  - 20220408
IS  - 2284-0729 (Electronic)
IS  - 1128-3602 (Linking)
VI  - 19
IP  - 23
DP  - 2015 Dec
TI  - Effects of atorvastatin combined with trimetazidine on myocardial injury and 
      inflammatory mediator in unstable angina patients during perioperative of 
      percutaneous coronary intervention.
PG  - 4642-6
LID - 9950 [pii]
AB  - OBJECTIVE: To investigate the effects of atorvastatin combined with trimetazidine 
      on periprocedural myocardial injury and serum inflammatory mediators in unstable 
      angina pectoris (UAP) patients following percutaneous coronary intervention (PCI) 
      treatment. PATIENTS AND METHODS: 90 patients with UAP treated with conventional 
      medications and PCI were recruited and were randomly divided into the control 
      group and the experimental group. The control group had 42 patients were treated 
      with atorvastatin alone, while the experimental group had 48 cases treated with 
      atorvastatin combined with trimetazidine. All the patients were checked the 
      preoperative 24h and postoperative 24h PCI concentrations of cardiac troponin I 
      (cTnI), hypersensitive C-reactive protein (hs-CRP), tumor necrosis factor-alpha 
      (TNF-alpha), serum interferon-gamma (IFN-gamma) and interlukin-10 (IL-10). RESULTS: At the 
      pre-PCI stage, every serum factors was no significant difference. 24 hours after 
      the PCI intervention, the occurence of abnormal cTnI level in the experimental 
      group was remarkable reduced than the control group. In the experimental group, 
      the serum levels of TNF-alpha and IFN-gamma significantly decreased (p < 0.05); while 
      IL-10 was increased. In the control group, all the mediators were increased 
      significantly except the hs-CRP (p < 0.05). CONCLUSIONS: No unexpected symptom 
      was found in patients with large dose atorvastatin combined with large dose 
      trimetazidine. The administration of conventional medications together with the 
      atorvastatin plus trimetazidine were able to reduce the prevalence of 
      postoperative myocardial injury.
FAU - Hao, J
AU  - Hao J
AD  - Department of Cardiology, The Second Hospital of Hebei Medical University, 
      Shijiazhuang, China. zhangjinyun2852@163.com.
FAU - Du, H
AU  - Du H
FAU - Li, W-W
AU  - Li WW
FAU - Zhao, Z-F
AU  - Zhao ZF
FAU - Liu, F
AU  - Liu F
FAU - Lu, J-C
AU  - Lu JC
FAU - Yang, X-C
AU  - Yang XC
FAU - Cui, W
AU  - Cui W
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Italy
TA  - Eur Rev Med Pharmacol Sci
JT  - European review for medical and pharmacological sciences
JID - 9717360
RN  - 0 (Inflammation Mediators)
RN  - 0 (Troponin I)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 82115-62-6 (Interferon-gamma)
RN  - 9007-41-4 (C-Reactive Protein)
RN  - A0JWA85V8F (Atorvastatin)
RN  - N9A0A0R9S8 (Trimetazidine)
SB  - IM
MH  - Aged
MH  - Angina, Unstable/blood/*drug therapy/epidemiology/*surgery
MH  - Atorvastatin/*administration & dosage/adverse effects
MH  - C-Reactive Protein/metabolism
MH  - Combined Modality Therapy
MH  - Drug Therapy, Combination
MH  - Female
MH  - Heart Injuries/blood/*epidemiology
MH  - Humans
MH  - Inflammation Mediators/*blood
MH  - Interferon-gamma/blood
MH  - Male
MH  - Middle Aged
MH  - Percutaneous Coronary Intervention/*methods
MH  - Perioperative Period
MH  - Postoperative Complications/blood/epidemiology
MH  - Trimetazidine/*administration & dosage/adverse effects
MH  - Troponin I/blood
MH  - Tumor Necrosis Factor-alpha/blood
EDAT- 2015/12/25 06:00
MHDA- 2016/08/09 06:00
CRDT- 2015/12/25 06:00
PHST- 2015/12/25 06:00 [entrez]
PHST- 2015/12/25 06:00 [pubmed]
PHST- 2016/08/09 06:00 [medline]
AID - 9950 [pii]
PST - ppublish
SO  - Eur Rev Med Pharmacol Sci. 2015 Dec;19(23):4642-6.